What to expect in the uniQure N.V. interview process

Based on publicly available sources, uniQure N.V. is a publicly traded biotechnology research company headquartered in Amsterdam, Netherlands, founded in 1998. The company specializes in genomic medicine and gene therapies—such as HEMGENIX for hemophilia B and clinical-stage assets like AMT-130 for Huntington's disease—with a workforce distributed across seven countries, including the United States, Switzerland, Bulgaria, and Germany.

Public data indicates that uniQure has undergone significant organizational restructuring and workforce reductions. Company records show that employee counts dropped sharply from approximately 480 personnel in December 2023 to around 209 by December 2024, representing a reduction of over 56%, with subsequent reports placing total headcount between 209 and 237 employees. The company operates in a competitive biotech landscape alongside peers like Spark Therapeutics, Denali Therapeutics, and Poseida Therapeutics, and has completed acquisitions such as AMT Biopharma and Corlieve Therapeutics. Financial and operational filings also highlight active corporate transactions, including an upsized $259 million public offering and notable insider stock sales in mid-2026.

While the search results provide extensive data regarding uniQure's clinical pipeline, market cap of approximately $240.1 million, and corporate milestones, they contain no direct employee reports concerning day-to-day workplace culture, internal management styles, return-to-office mandates, or specific interview processes.